Senshio

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

ospemifen

Available from:

Shionogi B.V.

ATC code:

G03XC05

INN (International Name):

ospemifene

Therapeutic group:

Spolni hormoni in zdravila genitalni sistem,

Therapeutic area:

Postmenopavza

Therapeutic indications:

Senshio is indicated for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women.

Product summary:

Revision: 13

Authorization status:

Pooblaščeni

Authorization date:

2015-01-14

Patient Information leaflet

                                19
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Shionogi B.V.
Herengracht 464
1017 CA Amsterdam
Nizozemska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/14/978/001 7 filmsko obloženih tablet
EU/1/14/978/002 28 filmsko obloženih tablet
EU/1/14/978/003 84 filmsko obloženih tablet
13.
ŠTEVILKA SERIJE
Številka serije
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Senshio
17.
EDINSTVENA OZNAKA
–
DVODIMENZIONALNA ČRTNA KODA
_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA
– V BERLJIVI OBLIKI_ _
PC
SN
NN
20
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI
DVOJNEM TRAKU
PRETISNI OMOT
1.
IME ZDRAVILA
Senshio 60 mg filmsko obložene tablete
ospemifen
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Shionogi
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Številka serije
5.
DRUGI PODATKI
pon
tor
sre
čet
pet
sob
ned
21
B. NAVODILO ZA UPORABO
22
NAVODILO ZA UPORABO
SENSHIO 60 MG FILMSKO O
BLOŽENE TABLETE
ospemifen
PRED ZAČETKOM UPORABE ZDRAVILA NATANČNO PREBERITE NAVODILO, KER
VSEBUJE ZA VAS POMEMBNE
PODATKE!
-
Navodilo shranite. Morda ga boste želeli ponovno prebrati.
-
Če imate dodatna vprašanja, se posvetujte z zdravnikom ali
farmacevtom.
-
Zdravilo je bilo predpisano vam osebno in ga ne smete dajati drugim.
Njim bi lahko celo
škodovalo, čeprav imajo znake bolezni, podobne vašim.
-
Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom
ali farmacevtom. Posvetujte
se tudi, če opazite katere koli neželene učinke, ki niso navedeni v
tem navodilu. Glejte
poglavje 4.
KAJ VSEBUJE NAVODILO
1.
Kaj je zdravilo Senshio in za kaj ga uporabljamo
2.
Kaj morate vedeti, preden boste vzeli zdravilo Senshio
3.
Kako jemati zdravilo Senshio
4.
Možni neželeni učinki
5.
Shranjevanje zdravila Senshio
6.
Vsebina pakiranja in dodatne informacije
1.
KAJ JE
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
_ _
Senshio 60 mg filmsko obložene tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Ena filmsko obložena tableta vsebuje 60 mg ospemifena.
Pomožna(e) snov(i)
z znanim učinkom
Ena filmsko obložena tableta vsebuje 1,82 mg laktoze v obliki
monohidrata.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
Filmsko obložena tableta (tableta)
Ovalne, bikonveksne, bele do belkaste, filmsko obložene tablete z
dimenzijami 12 mm x 6,45 mm, z
vtisnjeno oznako "60" na eni strani.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
_ _
Zdravilo Senshio je indicirano za zdravljenje zmerne do hude
simptomatske atrofije vulve in vagine
(VVA, _vulvar and vaginal atrophy_) pri ženskah po menopavzi.
4.2
ODMERJANJE IN NAČIN UPORABE
Odmerjanje
Priporočeni odmerek je ena 60 mg tableta enkrat na dan s hrano, vsak
dan ob istem času.
Če bolnica pozabi vzeti tableto, jo naj vzame skupaj s hrano takoj,
ko se spomni. Na isti dan bolnica
ne sme vzeti dvojnega odmerka.
Posebne populacije
_Starejši (>65_
_ let) _
Pri bolnicah, starih več kot 65 let, odmerka ni treba prilagajati
(glejte poglavje 5.2).
_Ledvična okvara_
_ _
Pri bolnicah z blago, zmerno ali hudo ledvično okvaro odmerka ni
treba prilagajati (glejte tudi
poglavje 5.2).
_Jetrna okvara _
Pri bolnicah z blago do zmerno jetrno okvaro odmerka ni treba
prilagajati._ _Ospemifena niso preučili
pri bolnicah s hudo jetrno okvaro, zato se uporaba zdravila Senshio
pri teh bolnicah ne priporoča
(glejte poglavje 5.2).
3
_Pediatrična populacija_
Zdravilo z ospemifenom ni namenjeno za uporabo pri pediatrični
populaciji za indikacijo zdravljenja
zmerne do hude simptomatske VVA pri ženskah po menopavzi.
Način uporabe
peroralna uporaba
Enkrat na dan se pogoltne ena tableta skupaj s hrano; jemlje naj se
vsak dan ob istem času.
4.3
KONTRAINDIKACIJE
Preobčutljivost na učinkovino (učinkovine) ali katero koli pomožno
snov, navedeno v poglavju 6.1.
Aktivna venska trombembolična bolezen ali vensk
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 08-03-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 08-03-2023
Public Assessment Report Public Assessment Report Bulgarian 05-07-2022
Patient Information leaflet Patient Information leaflet Spanish 08-03-2023
Public Assessment Report Public Assessment Report Spanish 05-07-2022
Patient Information leaflet Patient Information leaflet Czech 08-03-2023
Public Assessment Report Public Assessment Report Czech 05-07-2022
Patient Information leaflet Patient Information leaflet Danish 08-03-2023
Public Assessment Report Public Assessment Report Danish 05-07-2022
Patient Information leaflet Patient Information leaflet German 08-03-2023
Public Assessment Report Public Assessment Report German 05-07-2022
Patient Information leaflet Patient Information leaflet Estonian 08-03-2023
Public Assessment Report Public Assessment Report Estonian 05-07-2022
Patient Information leaflet Patient Information leaflet Greek 08-03-2023
Public Assessment Report Public Assessment Report Greek 05-07-2022
Patient Information leaflet Patient Information leaflet English 08-03-2023
Public Assessment Report Public Assessment Report English 05-07-2022
Patient Information leaflet Patient Information leaflet French 08-03-2023
Public Assessment Report Public Assessment Report French 05-07-2022
Patient Information leaflet Patient Information leaflet Italian 08-03-2023
Public Assessment Report Public Assessment Report Italian 05-07-2022
Patient Information leaflet Patient Information leaflet Latvian 08-03-2023
Public Assessment Report Public Assessment Report Latvian 05-07-2022
Patient Information leaflet Patient Information leaflet Lithuanian 08-03-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 08-03-2023
Public Assessment Report Public Assessment Report Lithuanian 05-07-2022
Patient Information leaflet Patient Information leaflet Hungarian 08-03-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 08-03-2023
Public Assessment Report Public Assessment Report Hungarian 05-07-2022
Patient Information leaflet Patient Information leaflet Maltese 08-03-2023
Public Assessment Report Public Assessment Report Maltese 05-07-2022
Patient Information leaflet Patient Information leaflet Dutch 08-03-2023
Public Assessment Report Public Assessment Report Dutch 05-07-2022
Patient Information leaflet Patient Information leaflet Polish 08-03-2023
Public Assessment Report Public Assessment Report Polish 05-07-2022
Patient Information leaflet Patient Information leaflet Portuguese 08-03-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 08-03-2023
Public Assessment Report Public Assessment Report Portuguese 05-07-2022
Patient Information leaflet Patient Information leaflet Romanian 08-03-2023
Public Assessment Report Public Assessment Report Romanian 05-07-2022
Patient Information leaflet Patient Information leaflet Slovak 08-03-2023
Public Assessment Report Public Assessment Report Slovak 05-07-2022
Patient Information leaflet Patient Information leaflet Finnish 08-03-2023
Public Assessment Report Public Assessment Report Finnish 05-07-2022
Patient Information leaflet Patient Information leaflet Swedish 08-03-2023
Public Assessment Report Public Assessment Report Swedish 05-07-2022
Patient Information leaflet Patient Information leaflet Norwegian 08-03-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 08-03-2023
Patient Information leaflet Patient Information leaflet Icelandic 08-03-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 08-03-2023
Patient Information leaflet Patient Information leaflet Croatian 08-03-2023
Public Assessment Report Public Assessment Report Croatian 05-07-2022

Search alerts related to this product

View documents history